Streetbeat News

Stock Prices

HEPS

D-Market Electronic reported significant growth in Q1 2024, with GMV increasing by 42.5% YoY to TRY 36.3 billion, revenue up by 45.0% YoY, and a notable improvement in EBITDA. The company also saw a rise in the number of orders, active customers, and free cash flow turning positive.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:11 am

AVGO

Broadcom shares are trading higher after the company reported better-than-expected Q2 financial results, issued strong revenue guidance, and announced a 10-for-1 forward split.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:10 am

PLNT

Planet Fitness has entered a $280 million Accelerated Share Repurchase (ASR) agreement with Citibank. This is part of its previously announced $500 million share repurchase authorization from November 8, 2022.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:06 am

MRNA

Moderna announced that its mRNA-1283 vaccine met its primary efficacy endpoint in a Phase 3 trial, indicating positive results for the vaccine's effectiveness.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:04 am

ALDX

Aldeyra Therapeutics has completed enrollment for its Phase 3 trial of Reproxalap, a treatment for dry eye disease. The company expects to release clinical trial results and potentially resubmit a New Drug Application in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:04 am

LOVE

Lovesac (NASDAQ:LOVE) reported Q1 EPS of $(0.83), beating the $(0.96) estimate, and sales of $132.64M, beating the $128.07M estimate. Despite the beats, EPS decreased by 196.43% and sales decreased by 6.06% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:03 am

VANI

Vivani Medical, Inc. (NASDAQ:VANI) announced that the FDA has cleared its Investigational New Drug Application for NPM-119, allowing the commencement of the LIBERATE-1 Phase 1 trial. This trial will evaluate the safety, tolerability, and pharmacokinetics of Vivani’s six-month GLP-1 implant for type 2 diabetes. The study is set to start in the second half of the year. Vivani is also developing other drug implants targeting chronic weight management.

Portfolio Pulse from Akanksha Bakshi

June 13, 2024 | 11:01 am

SIG

Signet Jewelers has reaffirmed its FY25 outlook, projecting total sales between $6.66 billion and $7.02 billion, which is in line with estimates. The company also expects same-store sales to range from a decline of 4.5% to an increase of 0.5%, and adjusted EPS between $9.90 and $11.52, compared to the estimated $10.55.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:01 am

VANI

Vivani Medical announced that their upcoming study will be the first clinical application of NanoPortal, their proprietary implant platform technology.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:00 am

VANI

Vivani Medical is studying NPM-119 to address medication non-adherence and improve tolerability issues associated with oral and injectable type 2 diabetes medications.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:00 am